Gómez CJF, Sanders MK, Laguna JFD, Montaño AC

Language: Spanish
References: 34
Page: 36-44
PDF size: 913.74 Kb.

ABSTRACT

Bisphosphonates are analogues of inorganic pyrophosphates, have a high affinity to calcium and are targeted to areas of bone turnover having preferential uptake on the exposed hydroxyapatite actively undergoing bone resorption. Bisphosphonate-related to the osteonecrosis of the jaws (BON) is defined as an exposed bone in the mandible, maxilla or both that persists for at least 8 weeks, in the absence of previous radiation and of metastasis in the jaws.
Recently, investigators have reported cases of BON in the medical and dental literature describing patients with various types of cancer receiving intravenous bisphosphonates to control and treat metastatic bone disease. Additionally, researchers have reported a few cases of BON in patients taking oral doses of alendronate to treat osteoporosis. In this paper, our goal is to educate dentist about the risk of patients undergo bisphosphonate treatment for osteonecrosis of the jaw.

REFERENCES

1. Gutta y col, 2007; Gutta R, Louis PJ. Bisphosphonates and osteonecrosis of the jaws: science and rationale. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007; 104 (2):186-93.

2. Murray, 2008). Murray DJ, Vesely MJ, Novak CB, Irish J, Crump M, Neligan PC. Bisphosphonates and avascular necrosis of the mandible: Case report and review of the literature. J Plast Reconstr Aesthet Surg. 2008; 61(1):94-8.

3. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007; 65(3):369-76.

4. Edwards BJ, Hellstein JW, Jacobsen PL, Kaltman S, Mariotti A, Migliorati CA. ADA report of the Council on Scientific Affairs: dental management of patients receiving oral bisphosphonate therapy—expert panel recommendations. J Am Dent Assoc 2008; 137:1144-50.

5. Licata AA. Discovery, clinical development, and therapeutic uses of bisphosphonates. Ann Pharmacother. 2005; 39:668-677.

6. Lehenkari PP, Kellinsalmi M, Napankangas JP, Ylitalo KV, Monkkonen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite, Mol Pharmacol. 2002; 61: 1255–1262.

7. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates, Curr Osteoporos Rep. 2003; 1: 45–52.

8. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis, Pathol Oncol Res. 2001; 7: 14–23.

9. Yamada J, Tsuno NH, Kitayama J, Tsuchiya T, Yoneyama S, Asakage M, Okaji Y, Shuno Y, Nishikawa T, Tanaka J, Takahashi K, Nagawa H. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. : J Surg Res. 2009; 151(1):115-20.

10. Wood J, Bonjean K, Ruetz S, et al: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 302:1055, 2002.

11. Watts, 2003). Watts NB. Bisphosphonate treatment of osteoporosis, Clin Geriatr Med. 2003; 19(2):395-414.

12. De Lago y col, 2008). De lago AA, Parada TMG, Somera IJ. Prevalencia de osteoporosis en población abierta de la Ciudad de México. Ginecol Obstet Mex. 2008; 76 (5):261-6.

13. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005; 90:1294-301.

14. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-B. Managing the care of patients with bisphosphonate associated osteonecrosis An American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005; 136: 1658-1668.

15. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, Clézardin P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62:6538-44.

16. 16 . Reid IR, Bolland MJ, Grey AB : Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 2007; 41 (3):318-320.

17. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates.J Oral Maxillofac Surg. 2008; 66(5):839-847.

18. Marx RE, Sawatari Y, Fortin M et. al: Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws:Risk Factors, Recognition, Prevention and Treatment. J Oral Maxillofac Surg. 2005; 63:1567-1575.

19. Felsenberg D, Hoffmeister B, Amling M. Bisphosphonat terapie assoziierte. Kiefernekrozen Deutsches Arzteblatt. 2006; 46:A3078-A3080.

20. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007; 65(3):415-423.

21. Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry. J Am Dent Assoc. 2009; 140(1):61-66.

22. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the Jaws Associated With the Use of Bisphosphonates: a Review of 63 Cases. J Oral Maxillofac Surg . 2004;62:527–34.

23. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul 7;353(1):99-102; discussion 99-102.

24. Fehm (2009) Fehm T, Beck V, Banys M, Lipp HP, Hairass M, Reinert S, Solomayer EF, Wallwiener D, Krimmel M. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies. Gynecol Oncol. 2009; 112(3):605-9.

25. Epstein JB, Rea G, Wong FL, Spinelli J, Stevenson-Moore P. Osteonecrosis: study of the relationship of dental extractions in patients receiving radiotherapy. Head Neck Surg. 1987 Sep-Oct;10(1):48-54.

26. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo S-B. Managing the care of patients with bisphosphonate associated osteonecrosis An American Academy of Oral Medicine position paper. J Am Dent Assoc. 2005; 136: 1658-1668.

27. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the Jaws Associated With the Use of Bisphosphonates: a Review of 63 Cases. J Oral Maxillofac Surg . 2004;62:527–34.

28. Chaudhry AN, Ruggiero SL: Osteonecrosis and bisphosphonates in oral and maxillofacial surgery. Oral Maxillofac Surg Clin North Am. 2007; 19(2):199-206.

29. Hoff AO, Toth BB, Altundag K, Guarneri V , Adamus A, Nooka AK, Sayegh GG, Johnson MM, Gagel RF, Hortobagyi GN. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. J

30. Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Teresa Ambrosini M, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma. 2008 ; 49(11):2156-2162.

31. American Dental Association. Obtaining Informed Consent Relating to Risks Associated with Oral Bisphosphonate Use. www.ada.org/prof/resources/topics/topics_osteonecrosis_consent.pdf - (consultado en enero de 2009).

32. Katz H. Endodontic Implications of Bisphosphonate-Associated Osteonecrosis of the Jaws: A Report of Three Cases. Journal of Endodontics. 2005; 31 (11) 2005: 831-834.

33. Rinchuse DJ, Rinchuse DJ, Sosovicka MF, Robison JM, Pendleton R. Orthodontic treatment of patients using bisphosphonates: a report of 2 cases. Am J Orthod Dentofacial Orthop. 2007; 131(3):321-6.

34. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol. 2009; 20(1):137-45.